Cargando…

Fibronectin rescues estrogen receptor α from lysosomal degradation in breast cancer cells

Estrogen receptor α (ERα) is expressed in tissues as diverse as brains and mammary glands. In breast cancer, ERα is a key regulator of tumor progression. Therefore, understanding what activates ERα is critical for cancer treatment in particular and cell biology in general. Using biochemical approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampayo, Rocío G., Toscani, Andrés M., Rubashkin, Matthew G., Thi, Kate, Masullo, Luciano A., Violi, Ianina L., Lakins, Jonathon N., Cáceres, Alfredo, Hines, William C., Coluccio Leskow, Federico, Stefani, Fernando D., Chialvo, Dante R., Bissell, Mina J., Weaver, Valerie M., Simian, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080927/
https://www.ncbi.nlm.nih.gov/pubmed/29980625
http://dx.doi.org/10.1083/jcb.201703037
Descripción
Sumario:Estrogen receptor α (ERα) is expressed in tissues as diverse as brains and mammary glands. In breast cancer, ERα is a key regulator of tumor progression. Therefore, understanding what activates ERα is critical for cancer treatment in particular and cell biology in general. Using biochemical approaches and superresolution microscopy, we show that estrogen drives membrane ERα into endosomes in breast cancer cells and that its fate is determined by the presence of fibronectin (FN) in the extracellular matrix; it is trafficked to lysosomes in the absence of FN and avoids the lysosomal compartment in its presence. In this context, FN prolongs ERα half-life and strengthens its transcriptional activity. We show that ERα is associated with β1-integrin at the membrane, and this integrin follows the same endocytosis and subcellular trafficking pathway triggered by estrogen. Moreover, ERα(+) vesicles are present within human breast tissues, and colocalization with β1-integrin is detected primarily in tumors. Our work unravels a key, clinically relevant mechanism of microenvironmental regulation of ERα signaling.